Gilead hesitant to tout drug for AIDS prevention

Earlier this week researchers found that Gilead's Truvada, a commonly prescribed AIDS drug, prevented monkeys from contracting HIV, igniting hope that the drug could possibly serve as a preventative treatment in those who are at high risk for HIV. Surprisingly, Gilead is reluctant to capitalize on the excitement due to concerns that it will promote unsafe habits among its users. There are a growing number of reports of people experimenting with the off-label use of the drug and the NIH, CDC and the Bill and Melinda Gates Foundation are all bankrolling human trials of Truvada for HIV prevention.

- read this article from the Associated Press for more

Sponsored By Metabolon

Five Translational Insights Key to a Successful First-in-Human (FIH) Study – Metabolite-Based Biomarker Discovery and Validation

Translational success rates from pre-clinical animal studies to human clinical trials remain frustratingly low. Learn how metabolomics helps you bridge between the theoretical & practical, between the function & actual activity of your drug molecule to get you closer to the phenotype, sooner.